share_log

6-K: Report of foreign private issuer (related to financial reporting)

6-K: Report of foreign private issuer (related to financial reporting)

6-K:外國發行人報告(業績相關)
美股SEC公告 ·  2024/12/19 00:09

牛牛AI助理已提取核心訊息

NeuroSense Therapeutics provided a business update and Q3 2024 financial results. The company completed its 18-month Phase 2b PARADIGM study for PrimeC in ALS, showing 33% slowed disease progression and 58% improved survival rates. NeuroSense received positive FDA feedback on Phase 3 study design and plans to commence in mid-2025.The company secured a $5M private placement and is pursuing early commercialization in Canada with potential launch in 2026. Q3 financials show R&D expenses of $4.61M, down 14% YoY, and G&A expenses of $3.52M. Cash position was $0.34M as of September 30, not including the December $5M financing.NeuroSense believes it has regained compliance with Nasdaq's $2.5M minimum shareholders' equity requirement. The company is progressing towards partnering opportunities for the Phase 3 study and Canadian market entry, with CEO Alon Ben-Noon stating they are approaching a key inflection point in development.
NeuroSense Therapeutics provided a business update and Q3 2024 financial results. The company completed its 18-month Phase 2b PARADIGM study for PrimeC in ALS, showing 33% slowed disease progression and 58% improved survival rates. NeuroSense received positive FDA feedback on Phase 3 study design and plans to commence in mid-2025.The company secured a $5M private placement and is pursuing early commercialization in Canada with potential launch in 2026. Q3 financials show R&D expenses of $4.61M, down 14% YoY, and G&A expenses of $3.52M. Cash position was $0.34M as of September 30, not including the December $5M financing.NeuroSense believes it has regained compliance with Nasdaq's $2.5M minimum shareholders' equity requirement. The company is progressing towards partnering opportunities for the Phase 3 study and Canadian market entry, with CEO Alon Ben-Noon stating they are approaching a key inflection point in development.
NeuroSense Therapeutics提供了業務更新和2024年第三季度財務報告。該公司完成了爲期18個月的Phase 20億 PARADIGm研究,研究PrimeC在漸凍症中的效果,顯示疾病進展減緩了33%,生存率提高了58%。NeuroSense收到了FDA關於第三階段研究設計的積極反饋,並計劃在2025年中期開始研究。該公司獲得了500萬美元的定向增發,並正在加拿大推進早期商業化,可能會在2026年推出。第三季度財務數據顯示,研發費用爲461萬美元,同比下降14%,總務和行政費用爲352萬美元。截止到9月30日的現金頭寸爲34萬美元,不包括12月份的500萬美元融資。NeuroSense相信它已經重新符合納斯達克250萬美元的最低股東權益要求。該公司正在推進與第三階段研究和進入加拿大市場的合作機會,首席執行官Alon Ben-Noon表示,他們正朝着開發中的關鍵轉折點邁進。
NeuroSense Therapeutics提供了業務更新和2024年第三季度財務報告。該公司完成了爲期18個月的Phase 20億 PARADIGm研究,研究PrimeC在漸凍症中的效果,顯示疾病進展減緩了33%,生存率提高了58%。NeuroSense收到了FDA關於第三階段研究設計的積極反饋,並計劃在2025年中期開始研究。該公司獲得了500萬美元的定向增發,並正在加拿大推進早期商業化,可能會在2026年推出。第三季度財務數據顯示,研發費用爲461萬美元,同比下降14%,總務和行政費用爲352萬美元。截止到9月30日的現金頭寸爲34萬美元,不包括12月份的500萬美元融資。NeuroSense相信它已經重新符合納斯達克250萬美元的最低股東權益要求。該公司正在推進與第三階段研究和進入加拿大市場的合作機會,首席執行官Alon Ben-Noon表示,他們正朝着開發中的關鍵轉折點邁進。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。